Search research articles
Contact Us
Filters
Showing results (61-70 of 71) with videos related to
Page
of 8
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 20, 2018
Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)
N Boku, M-H Ryu, K Kato, et al.
British Journal of Cancer
|
March 15, 2012
Safety of UFT/LV and S-1 as adjuvant therapy for stage III colon cancer in phase III trial: ACTS-CC trial
I Mochizuki, H Takiuchi, K Ikejiri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 19, 2015
A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer
M Ueno, T Okusaka, Y Omuro, et al.
ESMO Gastrointestinal Oncology
|
February 6, 2026
Prognostic factors for overall survival in advanced digestive neuroendocrine carcinoma treated with first-line cisplatin-based chemotherapy: a <i>post hoc</i> analysis of JCOG1213
H Hirano, K Hirata, Y Honma, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 20, 2014
S-1 as adjuvant chemotherapy for stage III colon cancer: a randomized phase III study (ACTS-CC trial)
M Yoshida, M Ishiguro, K Ikejiri, et al.
ESMO Open
|
March 14, 2021
S-1 and oxaliplatin versus tegafur-uracil and leucovorin as post-operative adjuvant chemotherapy in patients with high-risk stage III colon cancer: updated 5-year survival of the phase III ACTS-CC 02 trial
J Watanabe, S Sasaki, T Kusumoto, et al.
ESMO Gastrointestinal Oncology
|
February 6, 2026
WJOG18524G: a single-arm phase II study evaluating bemarituzumab combined with ramucirumab and paclitaxel in fibroblast growth factor receptor 2b (FGFR2b)-positive advanced gastric or gastroesophageal junction cancer (RAINBIRD)
K Shimozaki, K Hirata, H Hayashi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 28, 2018
Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300
Y-J Bang, E Yañez Ruiz, E Van Cutsem, et al.
Journal of Cancer Research and Clinical Oncology
|
February 18, 2017
Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer
Takuji Okusaka, H Miyakawa, H Fujii, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 29, 2015
Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS)
M-H Ryu, E Baba, K H Lee, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 71) with videos related to
Sort By:
Page
of 8
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 20, 2018
Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)
N Boku, M-H Ryu, K Kato, et al.
British Journal of Cancer
|
March 15, 2012
Safety of UFT/LV and S-1 as adjuvant therapy for stage III colon cancer in phase III trial: ACTS-CC trial
I Mochizuki, H Takiuchi, K Ikejiri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 19, 2015
A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer
M Ueno, T Okusaka, Y Omuro, et al.
ESMO Gastrointestinal Oncology
|
February 6, 2026
Prognostic factors for overall survival in advanced digestive neuroendocrine carcinoma treated with first-line cisplatin-based chemotherapy: a <i>post hoc</i> analysis of JCOG1213
H Hirano, K Hirata, Y Honma, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 20, 2014
S-1 as adjuvant chemotherapy for stage III colon cancer: a randomized phase III study (ACTS-CC trial)
M Yoshida, M Ishiguro, K Ikejiri, et al.
ESMO Open
|
March 14, 2021
S-1 and oxaliplatin versus tegafur-uracil and leucovorin as post-operative adjuvant chemotherapy in patients with high-risk stage III colon cancer: updated 5-year survival of the phase III ACTS-CC 02 trial
J Watanabe, S Sasaki, T Kusumoto, et al.
ESMO Gastrointestinal Oncology
|
February 6, 2026
WJOG18524G: a single-arm phase II study evaluating bemarituzumab combined with ramucirumab and paclitaxel in fibroblast growth factor receptor 2b (FGFR2b)-positive advanced gastric or gastroesophageal junction cancer (RAINBIRD)
K Shimozaki, K Hirata, H Hayashi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 28, 2018
Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300
Y-J Bang, E Yañez Ruiz, E Van Cutsem, et al.
Journal of Cancer Research and Clinical Oncology
|
February 18, 2017
Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer
Takuji Okusaka, H Miyakawa, H Fujii, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 29, 2015
Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS)
M-H Ryu, E Baba, K H Lee, et al.
Page
of 8